[ad_1]
A new HIV vaccine has shown promising results, according to a study published in the Lancet Journal.
The research claims that four vaccines were administered to 393 healthy adults for 48 weeks and created immune responses against HIV. At the same time, a parallel study was conducted on rhesus monkeys that were administered the vaccine combination to test for resistance to a virus similar to HIV, called simian-human immunodeficiency virus.
The vaccine will now be tested on 2,600 women in southern Africa who are at risk of contracting HIV.
"These results show that the Ad26 Prime, Ad26 plus gp140 mosaic boost the HIV vaccine induces robust immune responses in humans and monkeys with magnitude, kinetics, phenotype and durability and 67% protection against viruses in monkeys, "said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, at ContagionLive
added that these results should be interpreted with caution and that the verdict on this vaccine should be given after the second phase of the trials.
This is one of the HIV vaccines that need to be tested on humans in the space of 35 years.According to the data of the I & # 39; Approximately 36.7 million people were living with HIV in 2016, and nearly 1.8 million people were affected in the same year.
[ad_2]
Source link